No Data
No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com
Sector Update: Health Care
Pfizer CEO Says Tariff Uncertainty Is Deterring Further U.S. Investment in Manufacturing, R&D
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.